Narendra Bagri | Clinical Trials | Best Researcher Award

Published on by Top Pharmaceutical

Assoc. Prof. Dr. Narendra Bagri | Clinical Trials | Best Researcher Award

All India Institute of Medical Sciences | India

Assoc. Prof. Dr. Narendra Bagri is a distinguished clinician and academician in the field of pediatric rheumatology, presently serving as Additional Professor in the Department of Pediatrics, Division of Pediatric Rheumatology at the All India Institute of Medical Sciences (AIIMS), New Delhi, India. A graduate and postgraduate of the Institute of Medical Sciences, Banaras Hindu University, he has built a remarkable career through a blend of clinical excellence, teaching, and groundbreaking research in pediatric autoimmune and inflammatory disorders. He completed the prestigious PRES EMERGE Fellowship in Pediatric Rheumatology at the Bristol Royal Hospital for Children, UK, under the mentorship of Prof. A.V. Ramanan, enhancing his expertise in advanced pediatric rheumatologic care and translational research.Dr. Bagri’s scientific contributions encompass numerous impactful publications addressing critical aspects of pediatric inflammatory diseases, musculoskeletal imaging, and immunological mechanisms underlying juvenile idiopathic arthritis. His research includes the longitudinal analysis of multisystem inflammatory syndrome in children temporally related to COVID-19, the evaluation of pulse dexamethasone therapy in non-systemic juvenile idiopathic arthritis, and the technical and interpretive insights into pediatric musculoskeletal ultrasound. He has also authored work on the utility of musculoskeletal ultrasound in juvenile idiopathic arthritis, the forgotten figure in the history of methotrexate, sympathetic blocks for Raynaud’s phenomena in pediatric rheumatological disorders, and the conception of a national biologics registry for pediatric rheumatology.As a principal investigator and collaborator in multiple funded research projects by the Indian Council of Medical Research (ICMR) and the Science and Engineering Research Board (SERB), Dr. Bagri has contributed extensively to the understanding of synovial fluid proteomics, biomarker discovery, and immune-pathogenic mechanisms in childhood arthritis. His pioneering efforts include the development of transitional care services, collaborative rheumatology clinics, and the initiation of diagnostic and therapeutic procedures such as ultrasound-guided intra-articular injections and synovial biopsies.Dr. Bagri is a life member of several professional bodies, including the Indian Rheumatology Association, the Pediatric Rheumatology European Society, and the Indian Academy of Pediatrics. Recognized for his outstanding contributions, he has received multiple academic honors, travel grants, and leadership roles in national guideline formulation, including contributions to WHO and IAP documents on pediatric inflammatory syndromes. His dedication to research, patient care, and education continues to shape the evolution of pediatric rheumatology in India and beyond.

Profile: Google Scholar

Featured Publications

Bagri, N. K., Jose, B., Shah, S. K., Bhutia, T. D., Kabra, S. K., & Lodha, R. (n.d.). Impact of malnutrition on the outcome of critically ill children. The Indian Journal of Pediatrics, 82(7), 601–605.

Sivasubbu, S., & Scaria, V. (n.d.). Genomics of rare genetic diseases—experiences from India. Human Genomics.

Basu, S., Kumar, A., Kapoor, K., Bagri, N. K., & Chandra, A. (n.d.). Neonatal endogenous endophthalmitis: A report of six cases. Pediatrics.

Bagri, N., Saha, A., Chandelia, S., Dubey, N. K., Bhatt, A., Rai, A., & Bhattacharya, S. (n.d.). Fireworks injuries in children: A prospective study during the festival of lights. Emergency Medicine Australasia.

Bagri, N. K., Yadav, D. K., Agarwal, S., Aier, T., & Gupta, V. (n.d.). Pericardial effusion in children: Experience from tertiary care center in northern India. Indian Pediatrics.

Kumar, A., Bagri, N. K., Basu, S., & Asthana, R. K. (n.d.). Zinc supplementation for neonatal hyperbilirubinemia: A randomized controlled trial. Indian Pediatrics.

Bagri, N. K., Deepak, R. K., Meena, S., Gupta, S. K., Prakash, S., Setlur, K., Satapathy, J., Chopra, K., Upadhyay, A. D., Ramakrishnan, S., Lodha, R., Dar, L., Trikha, A., & Kabra, S. K. (n.d.). Outcomes of multisystem inflammatory syndrome in children temporally related to COVID-19: A longitudinal study. Rheumatology International.

Gupta, D., Thakral, D., Kumar, P., Kabra, S. K., Lodha, R., Kumari, R., Mohanty, S. K., … & Bagri, N. K. (n.d.). Primary immunodeficiency disorders among north Indian children. The Indian Journal of Pediatrics.

Aiyin Chen | Clinical Trials | Best Researcher Award

Published on by Top Pharmaceutical

Dr. Aiyin Chen | Clinical Trials | Best Researcher Award

Associate Professor at Oregon Health & Science University | United States

Dr. Aiyin Chen is an accomplished ophthalmologist and glaucoma specialist, recognized for her expertise in clinical care, research, and academic leadership. She serves as an Associate Professor in the Department of Ophthalmology at Oregon Health & Science University’s Casey Eye Institute. Dr. Chen’s career bridges advanced patient care with groundbreaking research in glaucoma detection, machine learning risk prediction, and optical coherence tomography applications. She has led and collaborated on multiple NIH-funded projects, contributed extensively to peer-reviewed literature, and worked to improve vision health in underserved populations. Dedicated to advancing ophthalmic science, Dr. Chen’s work continues to shape the future of glaucoma care.

Publication Profile 

Google Scholar

Education 

Dr. Aiyin Chen earned her Bachelor of Arts degree in Biological Sciences with a Neurobiology and Behavior concentration from Cornell University, graduating magna cum laude with distinction. She obtained her Doctor of Medicine with thesis distinction from the University of California, San Francisco (UCSF) School of Medicine. Following medical school, she completed a transitional internship at Atlantic Health Morristown Memorial Hospital and Mount Sinai School of Medicine. Dr. Chen then pursued ophthalmology residency training and a glaucoma fellowship at UCSF. She is certified by the American Board of Ophthalmology and holds active medical licenses in Oregon, Washington, and California, with prior licensure in Nevada.

Experience 

Dr. Aiyin Chen professional journey includes service as a glaucoma specialist at Wellish Vision Institute, and surgical roles at Sunrise Hospital and Box Canyon Surgery Center in Las Vegas. She transitioned to academia at the Casey Eye Institute, Oregon Health & Science University, where she served as Assistant Professor before advancing to Associate Professor. Her clinical expertise encompasses complex glaucoma management and surgery, while her administrative and teaching roles support training the next generation of ophthalmologists. Dr. Chen has been deeply involved in multi-institutional research collaborations, NIH-funded studies, and projects integrating telemedicine and big data analytics to improve glaucoma detection, diagnosis, and patient outcomes.

Awards and Honors 

Dr. Aiyin Chen has earned multiple distinctions throughout her academic and professional career, including thesis distinction during her MD program and recognition for her NIH-funded research contributions in ophthalmology. She has been selected as a K12 Clinical Scientist Institutional Career Development Awardee, underscoring her leadership in translational research. Her grant portfolio includes principal investigator and co-investigator roles on high-impact glaucoma studies funded by the National Eye Institute and National Library of Medicine. Dr. Chen’s scholarship, mentorship, and commitment to improving vision health in underserved communities have established her as a leader in ophthalmic research, earning her recognition among peers in the global vision science community.

Research Focus 

Dr. Aiyin Chen research focuses on advancing glaucoma detection, risk prediction, and disease management through technology-driven approaches. Her work includes developing machine learning models to predict glaucoma onset and progression, exploring the use of optical coherence tomography angiography for early diagnosis, and designing telemedicine-based screening strategies for underserved areas. She has contributed to studies evaluating clinic efficiency through data modeling and examined ocular blood flow in glaucoma patients before and after surgical interventions. With a strong record of NIH-funded research, Dr. Chen’s efforts aim to integrate imaging, big data analytics, and community outreach to improve glaucoma care worldwide.

Publication Top Notes

Does in vitro susceptibility predict clinical outcome in bacterial keratitis?

Measuring glaucomatous focal perfusion loss in the peripapillary retina using OCT angiography

Semaglutide and nonarteritic anterior ischemic optic neuropathy

Scleral intraocular pressure measurement in cadaver eyes pre-and postkeratoprosthesis implantation

Patterns of neural activation associated with exposure to odors from a familiar winner in male golden hamsters

Asian herbal-tobacco cigarettes:“not medicine but less harmful”?

Effect of algorithms and covariates in glaucoma diagnosis with optical coherence tomography angiography

Focal loss analysis of nerve fiber layer reflectance for glaucoma diagnosis

Prediction of multiclass surgical outcomes in glaucoma using multimodal deep learning based on free-text operative notes and structured EHR data

Extraction of active medications and adherence using natural language processing for glaucoma patients

Integrating deep learning with electronic health records for early glaucoma detection: a multi-dimensional machine learning approach

Emerging frontline leaders’ voices in response to COVID-19 crisis

Surgical management of an optic nerve glioma with perineural arachnoidal gliomatosis growth pattern

Optical coherence tomographic angiography detects retinal vascular changes associated with pituitary adenoma

Muhammad Musa Khan | Drug Safety and Risk Management | Best Researcher Award

Published on by Top Pharmaceutical

Dr. Muhammad Musa Khan | Drug Safety and Risk Management | Best Researcher Award

Associate Researcher at Hainan Institute of Zhejiang University | China

Dr. Muhammad Musa Khan is a Pakistani entomologist and research scientist with an extensive background in agricultural entomology, insect toxicology, and pest management. Currently serving as an Associate Researcher at the Hainan Institute of Zhejiang University, China, he focuses on pesticide toxicity, ecological risk assessment, and resistance management in agroecosystems. His research spans ecological, molecular, and toxicological approaches to pest control. Dr. Khan has published prolifically in high-impact journals and is recognized for advancing sustainable pest management strategies. His collaborative, multidisciplinary work integrates field ecology with molecular diagnostics, benefiting both science and agriculture on a global scale.

Publication Profile 

Google Scholar

Education 

Dr. Khan earned his Ph.D. in Agricultural Entomology and Pest Control from Huazhong Agricultural University, China, where he worked on predator safety in rice ecosystems. He completed his M.Sc. (Hons) in Entomology from the University of Agriculture Faisalabad, Pakistan, researching resistance mechanisms in cotton against sap-sucking pests. His undergraduate degree (B.Sc. Hons) in Agriculture with a specialization in Entomology was obtained from PMAS Arid Agriculture University, Rawalpindi. Additionally, he interned at the Nuclear Institute for Agriculture and Biology, gaining hands-on expertise in biological control agent rearing and field application methods.

Experience 

Dr. Khan currently serves as Associate Researcher at the Hainan Institute of Zhejiang University, China, investigating pesticide toxicity and resistance in brown planthopper and rice ecosystems. His previous role as a Postdoctoral Researcher at South China Agricultural University involved studying the effects of UV light on whiteflies and moths. During his Ph.D., he explored ecotoxicological risks of insecticides on beneficial insects and tested essential oil-based pest repellent strategies. His scientific skillset encompasses molecular biology techniques, gene expression analysis, bioinformatics, and biostatistics. His interdisciplinary approach allows integration of molecular diagnostics with field-level pest management.

Awards and Honors 

Dr. Khan has received significant recognition for his impactful research, including editorial contributions to international journals such as Frontiers in Plant Science. His publications have consistently appeared in top-tier Q1 journals like Journal of Hazardous Materials and Chemosphere. As a corresponding author and equal first author, his contributions are well-acknowledged in international collaborations. His work has received citations and global visibility for its originality in ecological toxicology and entomological innovation. Moreover, his involvement in multiple Chinese institutions and his role in international research networks reflect his growing influence and leadership in the agricultural research community.

Research Focus 

Dr. Khan’s research bridges entomology, toxicology, and molecular biology with a primary focus on insecticide resistance, non-target toxicity, and ecological safety in agroecosystems. He specializes in assessing chemical and environmental stressors on pests and their natural enemies, especially in rice and vegetable production systems. His studies utilize DNA/RNA techniques, gene expression profiling, and biochemical assays to decipher the molecular impact of pesticides and ultraviolet exposure on pest physiology and behavior. He is particularly interested in predator-prey dynamics, pollinator safety, integrated pest management, and sustainable solutions to enhance agricultural productivity while minimizing ecological harm.

Publication Top Notes

Role of insect gut microbiota in pesticide degradation: a review

Metabolic-based insecticide resistance mechanism and ecofriendly approaches for controlling of beet armyworm Spodoptera exigua: a review

Impact of invasive ant species on native fauna across similar habitats under global environmental changes

Lethal and sublethal effects of emamectin benzoate on the rove beetle, Paederus fuscipes, a non-target predator of rice brown planthopper, Nilaparvata lugens

Identification of attractants from plant essential oils for Cyrtorhinus lividipennis, an important predator of rice planthoppers

Role of digestive protease enzymes and related genes in host plant adaptation of a polyphagous pest, Spodoptera frugiperda

Temperature-Dependent Functional Response of Harmonia axyridis (Coleoptera: Coccinellidae) on the Eggs of Spodoptera litura (Lepidoptera: Noctuidae) in …

Lethal and Sublethal Effects of Chlorpyrifos on Biological Traits and Feeding of the Aphidophagous Predator Harmonia axyridis

Sublethal effects of chlorantraniliprole on Paederus fuscipes (Staphylinidae: Coleoptera), a general predator in paddle field

Using a Two-Sex Life Table Tool to Calculate the Fitness of Orius strigicollis as a Predator of Pectinophora gossypiella

Insecticide resistance and detoxification enzymes activity in Nilaparvata lugens Stål against neonicotinoids

Emamectin benzoate induced enzymatic and transcriptional alternation in detoxification mechanism of predatory beetle Paederus fuscipes (Coleoptera: Staphylinidae) at the …

Subrata Kar | Clinical Trials | Best Researcher Award

Published on by Top Pharmaceutical

Dr. Subrata Kar | Clinical Trials | Best Researcher Award

Subrata Kar at Virginia Commonwealth University | United States

Dr. Subrata Kar is a distinguished interventional cardiologist and academic leader currently serving as Associate Professor of Medicine at Virginia Commonwealth University and Interventional Cardiologist at the Veterans Affairs Medical Center in Richmond, Virginia. With specialization in structural heart disease, peripheral vascular intervention, and advanced heart failure and transplant cardiology, Dr. Kar has held leadership roles at multiple prestigious institutions including UCLA, Texas Tech University, and NYC Health + Hospitals. He has been instrumental in launching advanced cardiology programs, mentoring trainees, and leading clinical and academic departments. His work reflects a deep commitment to patient care, education, and cardiovascular innovation.

Publication Profile 

Orcid

Education 

Dr. Kar earned his Doctor of Osteopathic Medicine from the New York College of Osteopathic Medicine, where he also completed a Neuroanatomy Fellowship. He holds dual bachelor’s degrees in Bio-Mathematics and Biology from Rutgers University. His post-graduate training includes an internal medicine residency at the Cleveland Clinic, followed by a cardiovascular medicine fellowship at the University of Missouri-Columbia. He further specialized with interventional cardiology fellowships at Stony Brook University and UCLA, where he also trained in structural and congenital heart disease. Additionally, he completed an advanced heart failure and transplant cardiology fellowship at NYU Langone Medical Center.

Experience 

Dr. Kar has served in diverse clinical, academic, and leadership roles across major medical institutions in the U.S. Currently an Interventional Cardiologist and Advanced Heart Failure specialist at VCU/VA Medical Center, he previously held senior positions at Middletown Medical, NYC Health + Hospitals, Texas Tech University, and UCLA. His roles have included Division Chief, Director of Interventional Cardiology, and Chair of Fellowship Selection Committees. He has also worked as a hospitalist at the Cleveland Clinic and a clinical instructor at UCLA. His experience reflects comprehensive expertise in interventional cardiology, structural heart interventions, and academic program development.

Awards and Honors 

Dr. Kar has received recognition for both clinical excellence and academic leadership. At UCLA and Texas Tech, he was instrumental in program development and fellowship training, earning him leadership roles such as Chair of the Academic Cardiology Section of the American College of Cardiology (Texas Chapter). He has been invited to present at national cardiology conferences and served on key committees evaluating trainee competency. His pioneering clinical program launches, particularly in interventional cardiology at Coney Island Hospital, highlight his innovation and impact. His mentorship and contributions to cardiology education have also been widely commended by academic and hospital leadership.

Research Focus 

Dr. Kar’s research centers on structural heart disease, adult congenital heart defects, interventional cardiology techniques, and advanced heart failure therapies. He has explored minimally invasive cardiovascular interventions, radiation reduction in catheterization procedures (KAR RAD study), and cardiac CT applications. He has presented nationally on outcomes in percutaneous valve procedures and congenital heart disease management. His work also includes developing safety protocols and training programs in cardiac catheterization labs. Through his research, he integrates clinical innovation with academic insight, advancing cardiovascular treatment and education, especially in underserved populations. His mentoring of trainees in research further amplifies his academic reach.

Publication Top Notes

Application and Outcomes of Minimal-Dose Versus Standard-Dose Radiation in Peripheral Endovascular Intervention (KAR Endovascular Study)